Telmisartan-poly (ethylene glycol) conjugate augmented drug dissolution and permeability in cervical cancer cells

  • Rahul Sharma
  • Satish Sardana
  • Jitender Madan
DOI https://doi.org/10.22270/jddt.v9i1.3724

Abstract

Telmisartan is currently reported for inhibiting cervical cancer cells. Despite favorable therapeutic profile, poor aqueous solubility and low oral bioavailability limit its therapeutic application in treatment of cervical cancer. Telmisartan was chemically conjugated to poly (ethylene glycol) through amide linkage to form telmisartan-PEG drug conjugate. Poly (ethylene glycol) with terminal –NH2 was conjugated with telmisartan via amide linkage. Telmisartan-PEG conjugate displayed peak at 1690 cm-1 for C=O group of amide linkage. Furthermore, telmisartan illustrated the crystalline lattice as compared to amorphous nature of telmisartan-PEG conjugate. The in vitro dissolution testing indicated that telmisartan displayed only 22.6±3.8% drug release from dialysis bag as compared (Two-way ANOVA test, P<0.05) to 76.9±5.4% from telmisartan-PEG conjugate. The therapeutic efficacy of telmisartan and telmisartan-PEG conjugate was analyzed in cervical cancer, HeLa cells. The IC50 of telmisartan in HeLa cells was estimated to be 48.6±6.9µM as compared (Two Way ANOVA test) to 17.2±2.7-µM of telmisartan-PEG conjugate dissolved in aqueous phase. In conclusion, telmisartan-PEG conjugate must be investigated under a set of stringent in vivo parameters for pharmacokinetic and pharmacodynamic studies. 


Keywords: Cervical cancer, telmisartan, poly (ethylene glycol), conjugate, dissolution, cytotoxicity

Downloads

Download data is not yet available.

References

1. Chen J.R., Yang Y.C., Chen T.C., Lai J.C., Chang S.J., Chang C.L., Wang K.L. Salvage chemotherapy in recurrent cervical cancer with biweekly pegylated liposomal Doxorubicin (lipo-dox). Taiwan J Obstet Gynecol. 2008; 47(3):322-6.
2. Casagrande N., De Paoli M., Celegato M., Borghese C., Mongiat M., Colombatti A., Aldinucci D. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecol Oncol. 2013; 131(3):744-52.
3. Sharma A., Jyoti K., Bansal V., Jain U.K., Bhushan B., Madan J. Soluble telmisartan bearing poly (ethylene glycol) conjugated chitosan nanoparticles augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in human cervical cancer cells. Mater Sci. Eng C. 2017; 72: 69-76.
4. Cho H.K., Cheong I.W., Lee J.M., Kim J.H. Polymeric nanoparticles, micelles and polymersomes from amphiphilic block copolymer. Korean J Chem Eng. 2010; 27:731–40.
5. Conover C.D., Greenwald R.B., Pendri A., Gilbert C.W., Shum K.L. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol. 1998; 42:407–414.
6. Liang N., Sun S., Gong X., Li Q., Yan P., Cui F. Polymeric Micelles Based on Modified Glycol Chitosan for Paclitaxel Delivery: Preparation, Characterization and Evaluation. Int J Mol Sci. 2018; 19(6): 1550.
7. Park J., Cho W., Cha K.H., Ahn J., Han K., Hwang S.J. Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process. Int J Pharm. 2013; 441: 50–55.
8. Matsuyama M., Funao K., Kuratsukuri K., Tanaka T., Kawahito Y., Sano H., Chargui J., Touraine J.L., Yoshimura N., Yoshimura R. Telmisartan inhibits human urological cancer cell growth through early apoptosis. ExpTher Med. 2010; 1: 301-306.
9. Lee L.D., Mafura B., Lauscher J.C., Seeliger H., Kreis M.E., Gröne, J. Antiproliferative and apoptotic effects of telmisartan inhuman colon cancer cells. Oncol Lett. 2014; 8: 2681-2686.
Statistics
71 Views | 32 Downloads
How to Cite
1.
Sharma R, Sardana S, Madan J. Telmisartan-poly (ethylene glycol) conjugate augmented drug dissolution and permeability in cervical cancer cells. JDDT [Internet]. 19Nov.2019 [cited 16Jan.2021];9(1):358-61. Available from: http://jddtonline.info/index.php/jddt/article/view/3724
Issue
Vol 9 No 1 (2019): Volume 9, Issue 1 Jan-Feb 2019
Section
Research
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).